High importance
Oct 27, 2026
This study is important as it explores a potential new treatment option for patients suffering from severe nosebleeds due to HHT. Though results suggest possibilities, discussions with healthcare providers about treatment options should continue.
To study whether daily use of Pazopanib over 24 weeks can reduce the severity of nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT).
Results showed that Pazopanib might help in reducing the severity of nosebleeds, but specific data and statistics are not provided in the source. Comprehensive safety and efficacy results are needed.
Patients participated in a trial where they received either the active medication (Pazopanib) or a placebo (an inactive sugar pill). The trial measured the severity and duration of nosebleeds, as well as blood loss and safety throughout the study.
The data on effectiveness and detailed results are not included, making it difficult to draw strong conclusions. The trial specifics imply further analysis is required for precise findings.
Status:
Phase: Phase 2, Phase 3
Eligibility: 18 Years – 85 Years · All sexes
Countries: United States
For your doctor:
ClinicalTrials.gov: NCT03850964
During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduce the severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia (HHT). Patients will either be provided active drug or a placebo \[sugar - inactive pill\], and be tested for nose bleed severity throughout the trial, including particularly nose bleed duration. Investigators will also test for blood loss, as well as for safety. This study is funded by the US Department of Defense USAMRAA and FDA/OOPD.